{"id":"open-single-period-a140","safety":{"commonSideEffects":[{"rate":"40-60%","effect":"Neutropenia"},{"rate":"30-50%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL5805487","moleculeType":null,"molecularWeight":"493.61"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD47 is a protein that inhibits phagocytosis, and by blocking it, A140 aims to enhance the immune system's ability to recognize and destroy cancer cells. This mechanism is thought to be particularly effective in treating hematological malignancies.","oneSentence":"A140 is a monoclonal antibody targeting CD47.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:27.351Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory acute myeloid leukemia"},{"name":"Relapsed or refractory non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT04835142","phase":"PHASE3","title":"Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC","status":"COMPLETED","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2020-12-31","conditions":"Metastatic Colorectal Cancer","enrollment":688}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["KL-140"],"phase":"phase_3","status":"active","brandName":"Open single period A140","genericName":"Open single period A140","companyName":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","companyId":"sichuan-kelun-biotech-biopharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A140 is being studied as a potential treatment for metastatic colorectal cancer in a Phase III clinical trial. In this trial, the efficacy and safety of A140, combined with mFOLFOX6, are being compared to Erbitux in patients with Ras wild-type metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}